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TGF-b type II receptor in rat renal vascular development: Localization
to juxtaglomerular cells. To further define the role of transforming growth
factor-beta (TGF-b) receptors in renal vascular development, detailed
immunohistochemical studies of TGF-b receptor expression were per-
formed from gestational day 15 through adulthood. On gestational day 15,
TGF-b type II receptor immunoreactivity was restricted to perirenal
stromal and vascular cells. On gestational day 17 TGF-b type II receptor
immunoreactive stromal cells were observed within the kidney, with the
same distribution as stromal a-smooth muscle actin and renin immuno-
reactive cells, and intense stromal TGF-b type II receptor immunoreac-
tivity continued through postnatal day 5. As vascular development pro-
gressed, TGF-b type II receptor, a-smooth muscle actin and renin
immunoreactivity became progressively restricted to small renal arteries
and arterioles. Expression of TGF-b type II receptors and renin was very
intense in afferent glomerular arterioles during postnatal days 5 to 15, and
then became progressively restricted only to juxtaglomerular cells in the
mature kidney. TGF-b type I receptor (ALK-5, ALK-1 and ALK-2)
immunoreactivity was not detected in stromal or vascular elements during
development or in the mature kidney. Intense TGF-b type II receptor
expression in renal stromal vascular smooth muscle cell precursors and
developing blood vessels suggests a role for the TGF-b type II receptors
in the formation of the renal vascular smooth muscle compartment. The
continued intense expression in juxtaglomerular cells argues for a role in
renin synthesis and/or release. The absence of ALK-5, ALK-1, and ALK-2
in developing vascular smooth muscle and mature juxtaglomerular cells
indicates that the canonical view of TGF-b signaling may not hold in these
locations.
Vascularization of the developing kidney occurs through the
processes of angiogenesis and in situ vasculogenesis [1–3]. Angio-
genesis refers to invasion by vascular sprouts that originate from
formed vessels outside the kidney and grow into it alongside the
ureteric bud, and vasculogenesis refers to new vessel formation in
situ from endothelial cell precursors. Except for some capillaries,
the forming blood vessels become progressively invested with
smooth muscle cells or pericytes. Renin producing cells of the
afferent glomerular arteriole represent specialized vascular
smooth muscle cells (VSMC), and glomerular mesangial cells are
pericytes.
It was long held that angiogenesis is the exclusive mechanism of
renal vascularization [4]. This view was based on the findings that
glomerular epithelium, but not blood vessels, can develop from
unvascularized metanephric blastema in vitro [5], and that trans-
plantation of unvascularized metanephric blastema onto a host
vascular bed results in the formation of blood vessels and glomer-
ular capillaries derived from the host [6, 7]. However, Abraham-
son and coworkers [3] recently showed that endothelial cell
precursors are present in metanephric blastema before angiogenic
sprouts are formed, and that they can develop into blood vessels
in the absence of angiogenesis from without [3], proving that in
situ vasculogenesis occurs during renal vascular development.
The mechanisms that stimulate organization of endothelial cell
precursors into tubes are as yet poorly understood. The angio-
genic mediators VEGF, angiopoietin-1, and angiopoietin-2 [1]
and transforming growth factor-beta (TGF-b) mediated signals
appear to be necessary. In this regard, we found that in vitro
capillary formation by glomerular endothelial cells requires intact
signaling via TGF-b type II receptors (TbR-II) [8]. Subsequently,
others reported similarly defective capillary tube formation in the
yolk sac in TGF-b1 knockout mice [9] and in mice deficient in
TbR-II [10].
Many endothelial cell tubes become invested with VSMC or
pericytes to form arteries, arterioles, veins and specialized struc-
tures like renal glomeruli. Signaling via platelet-derived growth
factor (PDGF) b receptor is critical for the development of
glomerular mesangial cells, as has been shown by the failure of
mesangial cell development in PDGF-B [11] and in PDGF
receptor b [12] knockout mice, but arterial VSMC development is
normal in these mice. In VSMC, TGF-b induces either prolifer-
ation or inhibition of growth, depending on VSMC lineage and
the abundance and subtype of TGF-b receptors [13]. Further,
TGF-b signals modulate PDGF effects in blood vessels in that
TGF-b1 up-regulates PDGF receptors in VSMC and mesangial
cells [14, 15], and stimulates PDGF-B expression by endothelial
cells [16]. These effects of TGF-b suggest that there may be a role
for this mediator in VSMC development.
The TGF-b receptor superfamily consists of two broad classes
of receptor serine threonine kinases, type I and type II. The type
I receptors are referred to as activin like kinases (ALK). Distinct
type II receptors for activin, bone morphogenic proteins and
TGF-b bind their appropriate ligand leading to type II receptor-
ALK dimerization with consequent transphosphorylation of the
respective ALK [17]. Six ALK isoforms are known: ALK-5
interacts with TbR-II [18, 19], ALK-2 and ALK-4 interact pre-
dominantly with activin type II receptors [19], and ALK-3 and
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Fig. 1. Localization of a-smooth muscle (a-
SM) actin, transforming growth factor-beta
type II receptor (TbR-II) and renin proteins
during renal development. Serial sections of
rat fetal kidneys at gestational days 15 (E15;
A-C) and 17 (E17; D-F) were stained with
antibodies directed against a-SM actin (A,
D), TbR-II (B, E) or renin (C, F).
Magnifications: 370 (A-C); 335 (D-F); 366
(insets in D-F). Strong a-SM actin
immunoreactivity is present in aorta of E15
rats (*). Stromal staining (3) for a-SM actin,
TbR-II and renin is observed in the perirenal
mesenchyme at E15 (A-C), and within the
kidneys at E17 (D-F). In panel F, gonadal
artery staining for renin is indicated by (Ü).
The insets in panels E and F show co-
localization of TbR-II and renin in stromal
cells.
Fig. 2. Localization of a-smooth muscle (a-
SM) actin, transforming growth factor-beta
type II receptor (TbR-II) and renin proteins
during renal development. Serial sections of
rat fetal kidneys at gestational day 19 (E19;
A-C) and postnatal day 5 (D-F) were stained
with antibodies directed against a-SM actin
(A, D) or TbR-II (B, E) or renin (C, F).
Magnifications: 335 (A-F); 366 (insets in
A-F). Alpha-SM actin, TbR-II and renin are
observed in stromal cells and in renal vessels
at E19 (A-C). On postnatal day 5 (D-F), a-
SM actin and TbR-II are found in stromal
cells and in renal blood vessels, while renin
tends to be more confined to blood vessels
(F).
ALK-6 are type I receptors for bone morphogenic protein [20].
We recently found much greater TbR-II and ALK-5, but not
ALK-2 mRNA expression in neonatal than in mature kidney [21].
Both TbR-II and ALK-5 were heavily expressed in ureteric bud
epithelial cells and in developing proximal tubule epithelium,
while expression of these receptors was not detectable by immu-
nohistochemistry in epithelial cells of the mature kidney. In the
same study, intense stromal TbR-II, but not ALK-5 expression
was found on neonatal day 1, though the identity of the stromal
cells was not known. Since stromal cells were previously shown to
express a-smooth muscle actin (a-SM actin) [22], the current
study sought evidence for TbR-II expression in the renal VSMC
during development. Our findings suggest that stromal TbR-II
immunoreactive cells are VSMC precursors, some of which also
express renin, and that they become associated with renal arte-
rioles. As development of the renal vasculature progresses,
TbR-II and renin display a remarkable level of co-localization.
Strong expression of both proteins in afferent arterioles during
early postnatal life later regresses, and both proteins continue to




Time-dated pregnant and adult Sprague-Dawley rats were
obtained from Charles River (Wilmington, MA, USA). The day
following overnight mating was defined as the first day of gesta-
tion [23]. On the day of study, rats were anesthetized with
methoxyfluorane and exsanguinated. Renal tissue was taken from
rats at gestational days 15, 17 and 19 (E15, E17 and E19,
respectively), postnatal days 1, 5, 10, 15 and 30 (P1, P5, P10, P15,
and P30, respectively) and from mature (M) rats. At each
developmental stage kidneys from three to nine rats were studied.
For rat embryos, the kidneys were removed together with the
other internal organs to facilitate identification. Only the kidneys
were taken from newborn and adult rats. Kidneys were fixed
immediately in 10% buffered formalin solution and embedded in
paraffin. Six-micrometer-thick serial sections were processed for
immunohistochemical analysis as described below.
Antibodies
Affinity-purified rabbit polyclonal antibody to human TbR-II
receptor (L-21, catalog number sc-400; Santa Cruz, CA, USA),
directed against amino acids 246-266 of the receptor was used at
a dilution of 1:750. This antibody preparation is known to detect
human, mouse, and rat TbR-II, and is not cross-reactive with
known activin like kinases (ALKs; type I receptors for the TGF-b
receptor superfamily that include activin and bone morphogenic
protein receptors).
Affinity-purified rabbit polyclonal antibody to human ALK-5
(V-22, cat.# sc-398; Santa Cruz), directed against amino acids
158-179 of ALK-5 was used at a dilution of 1:1000. This antibody
preparation detects human, rat and mouse ALK-5, and is not
cross-reactive with type II TGF-b receptor or other ALKs.
Affinity-purified rabbit polyclonal antibody, which recognizes
ALK-1 and ALK-2 (T-19, cat # sc-402; Santa Cruz), directed
against the carboxyterminus of ALK-1 was used at a dilution of
1:1500. This antibody preparation detects human, mouse and rat
ALK-1 and ALK-2, and is not cross-reactive with other receptor
serine-threonine kinases.
The highly specific rabbit polyclonal anti-rat renin antibody
[24], a kind gift of Dr. T. Inagami (Vanderbilt University,
Nashville, TN, USA), was used at a dilution of 1:2500.
A mouse monoclonal anti-human a-smooth muscle actin anti-
body (a-SM actin, clone No. 1A4; Sigma Chemical Co., St. Louis,
MO, USA) was used at a dilution of 1:400. This antibody is
directed against the amino terminal decapeptide sequence of
a-SM actin and detects only the a-SM isoform of actin [10–13].
Immunohistochemistry
The detection methods were previously described [21]. Slides
were deparaffinized with xylene followed by rehydration in de-
scending series of ethanols. Endogenous peroxidases were
quenched in 3% hydrogen peroxidase in methanol for 20 minutes.
For detection of renin and TGF-b receptors, the sections were
treated with 0.4% pepsin (Sigma) in 0.01 N HCl for 20 minutes at
37°C. For detection of a-SM actin, sections were microwave
treated. They were then rinsed with 0.5% milk (Carnation nonfat
dry milk) in Tris-buffered saline (TBS), blocked with 1% normal
goat serum (NGS) in 0.5% milk/TBS for 30 minutes, and incu-
bated overnight in a humidified chamber at 4°C with the respec-
tive primary antibodies. The sections were then rinsed in 0.5%
milk/TBS followed by incubation with a 1:200 dilution of biotin-
ylated secondary goat anti-rabbit IgG (Vector Laboratory, Bur-
lingame, CA, USA) for polyclonal antibodies or with a 1:500
dilution of biotinylated secondary goat anti-mouse IgG (Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA, USA) for
monoclonal antibody for 30 minutes. Both primary and secondary
antibodies were diluted in buffer containing 1% NGS in 0.5%
ml/TBS. The sections were rinsed again in 0.5% milk/TBS, then
incubated with the ExtrAvidin alkaline phosphatase (Sigma),
diluted 1:800 in Tris buffer, pH 8.2 for 60 minutes and washed one
final time in TBS, pH 8.2. The fast red alkaline phosphatase
substrate was prepared fresh from fast red K salt (Sigma) accord-
ing to the protocol described by Tubbs, Gephardt and Petras [25].
Unlike the fast red substrate tablets, the reaction product is not
soluble in organic solvents, and produces an intense red stain. For
some sections, the avidin-biotin-complex immunoperoxidase
method (ABC kit was from Vector Laboratories) that uses
3,39-diaminoanobenzidine as a substrate was used. After counter-
staining with Mayer’s modified hematoxylin (Polyscientific, Bay
Shore, NY, USA), the sections were washed in water, dehydrated
in an ascending ethanol series followed by xylene, and mounted
with a coverslip using Permount (Fisher Scientific, Pittsburgh, PA,
USA). The positive staining was red (or brown) on a blue
background. As negative controls, the primary antibody was
omitted or substituted with an irrelevant rabbit IgG. No staining
occurred in the control sections.
For co-localization, serial sections were examined. Sections
from three to five different stages of development (for instance,
E15, P1, mature) were mounted on the same slide to control for
variations in staining. Each slide was inspected for the presence,
pattern of distribution, and intensity of antibody staining in the
kidney. Staining intensity was graded semiquantitively from 0 to 4
(0 represents absence of staining and 4 indicates marked staining)
by two independent investigators, and the scores were averaged.
Liu and Ballermann: TGF-b receptors in renin producing cells718
RESULTS
Alpha-smooth muscle actin, TGF-b type II receptors and renin
expression
Figures 1 and 2 show immunohistochemical staining for a-SM
actin, TbR-II and renin in serial sections of kidney at different
stages of development. Figure 3 shows representative areas under
high-magnification. For each developmental stage results were
similar in three to nine separate specimens.
At E15, the kidneys consisted of loosely organized blastemal
cells and a few invading ureteric bud branches. At this stage of
development (Fig. 1 A-C), perirenal stroma and aorta were
stained intensely by a-SM actin antibodies. TbR-II immunoreac-
tivity was observed in the same location, though TbR-II staining
was much weaker than that of a-SM actin. Renin expression was
also observed in some perirenal cells associated with the aorta. At
E15, no a-SM actin, TbR-II or renin expression was observed
within the developing kidney.
At E17 (Fig. 1 D-F), branching ureteric bud structures and
several S-shaped bodies were seen in the mid-cortex. Blood
vessels strongly immunoreactive with anti-a-SM actin antibody
were observed alongside the developing ureter. In sections pre-
pared from the kidneys of three separate rats, TbR-II antibodies
strongly stained epithelial cells within the ureter, as well as
perirenal stromal cells at this stage of development, and TbR-II
immunoreactivity was present in loosely organized cells in the
region of invading blood vessels, but did not appear to co-localize
with a-SM actin in the blood vessels found adjacent to the ureter.
At E17 a-SM actin immunoreactivity was also found in loose,
lace-like stromal cells within the kidney parenchyma (Fig. 3A).
TbR-II and renin immunoreactivity similarly were localized to
such loosely organized stromal cells (Fig. 3 B,C). At E17, TbR-II
and renin continued to be expressed in perirenal cells, and strong
renin expression was consistently observed in the gonadal artery
(Fig. 1F).
At E19 (Fig. 2 A-C), numerous S-shaped bodies and ureteric
bud structures were observed in the outer cortical region of
nephron morphogenesis, and some mature glomeruli were seen.
Organized renal arterioles staining strongly with a-SM actin
antibodies were observed just below the region of nephron
morphogenesis. Such blood vessels also stained positively with
TbR-II and renin antibodies. Stromal cells continued to express
TbR-II, renin, and a-SM actin at this stage. S-shaped bodies were
uniformly negative for a-SM actin, TbR-II and renin immunore-
activity. Glomeruli stained weakly with a-SM actin (not shown),
but not with TbR-II or renin antibodies.
On postnatal day 5 (Fig. 2 D-F), a-SM actin, TbR-II and renin
continued to be co-expressed in developing blood vessels, and in
renal stromal cells. However, at this stage of development, renin
expression tended to localize predominantly to blood vessels,
while TbR-II and a-SM actin continued to be strongly ex-
pressed both in blood vessels and in the stroma. Again, S-shaped
bodies and primitive as well as more mature glomeruli were not
immunoreactive with TbR-II or renin antibodies; glomeruli
showed weak immunoreactivity with a-SM actin antibodies (not
shown). The pattern of TbR-II expression on postnatal day 1 was
similar to that observed on postnatal day 5, except that stromal
staining on postnatal day 1 was more intense (Fig. 5B) [21]. On
postnatal day 10, a-SM actin, TbR-II and renin all were strongly
expressed throughout afferent glomerular arterioles (Fig. 3 D-F),
while TbR-II and renin expression in interlobular arteries and
other large renal vessels was much less intense than on postnatal
day 5. On postnatal day 15 (not shown), a-SM actin expression
continued to be observed throughout the vasculature, TbR-II
staining was still observed in afferent arterioles, albeit at a lower
intensity than on postnatal day 5, and renin expression in afferent
arterioles had diminished compared to that found on postnatal
day 10. In kidneys from rats at postnatal day 30 (not shown), and
in adult kidneys a-SM actin (not shown) expression continued to
be observed in blood vessels throughout the kidney. By contrast,
TbR-II and renin expression were prominent only in juxtaglomer-
ular (JG) cells, where they co-localized (Fig. 3 G, H and 4E). In
serial sections from five separate mature rats that were evaluated
semiquantitatively (Fig. 4), TbR-II was observed almost without
exception in JG cells of superficial and deep glomeruli if renin
immunoreactivity was seen. A few intraglomerular cells immuno-
reactive with TbR-II antibodies were found near the vascular pole
of many glomeruli (Fig. 3G).
Figure 4 summarizes the findings for intensity of a-SM actin,
TbR-II and renin staining in renal stromal cells, interlobular
artery, afferent glomerular arterioles and juxtaglomerular cells as
a function of developmental stage. Alpha-smooth muscle actin
was found in renal artery and arterioles from the earliest point of
blood vessel ingrowth into the kidney, and continued to be
expressed throughout development, marking blood vessels that
had developed a smooth muscle cell layer. TbR-II and renin
immunoreactivities were first observed to be associated with
organized blood vessels at E19. Renin and TbR-II expression
were most intense in afferent arterioles during days 1 to 10 of
postnatal development. As development progressed, both renin
and TbR-II expression in renal blood vessels became restricted to
the afferent arterioles and then exclusively to JG cells. Renin
expression became confined to JG cells slightly earlier than
TbR-II expression.
TGF-b type I receptor expression
Since TbR-II forms a heteromeric signaling complex with type
I TGF-b receptors (ALK-5, ALK-1 and ALK-2), it was of interest
to further explore the potential co-expression of type I and type II
TGF-b receptors. Detailed work on ALK-5 expression was previ-
ously published [21]. The ALK-5, ALK-1 and ALK-2 antibodies
detected expression in proximal tubule and ureteric bud epithelial
cells beginning at E17 through P10. In contrast, TbR-II immuno-
reactivity was greatest in the stromal cells and in the developing
blood vessels. Neither ALK-5 nor ALK-1 or ALK-2 antibodies
co-localized with TbR-II to stromal or vascular smooth muscle
cells. Figure 5 A-C shows the distinct pattern of ALK-5, TbR-II,
ALK-1 and ALK-2 immunoreactivity on postnatal day 1. As
previously reported [21], ALK-5 immunoreactivity was strongest
in proximal tubule epithelium, while TbR-II was found predom-
inantly in the renal stroma, with weaker staining of proximal
tubule cells. ALK-1 and ALK-2 similarly were found in proximal
tubule epithelium, and in addition, strong co-localization of
TbR-II, ALK-1 and ALK-2 staining was observed in the transi-
tional epithelium of the calyceal system. Consistent with earlier
studies examining mRNA expression for ALK-5, ALK-2 and
TbR-II [21], adult kidneys (Fig. 5 D-I) and transitional epithelium
of calyces and ureter (not shown) were uniformly negative for
ALK-5, ALK-1 and ALK-2 immunoreactivity. In contrast, as
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noted above, very strong TbR-II immunoreactivity was observed
in JG cells of adult kidney (Fig. 5E and Fig. 2G).
DISCUSSION
The objective of this study was to explore the temporal and
spatial expression pattern of TbR-II during rat renal vascular
development, and to relate it to vascular a-SM actin, renin and
TGF-b type I receptor expression. Beginning at E17, there was
prominent TbR-II immunoreactivity within the kidney, in loosely
organized stromal cells that also expressed a-SM actin. A few
stromal cells also expressed renin. As development progressed,
TbR-II, a-SM actin and renin immunoreactivity became progres-
sively associated with the VSMC layer of developing blood vessels.
Intense TbR-II and renin expression were observed in afferent
arterioles on postnatal days 10 to 15. In the mature kidney,
TbR-II was strongly expressed only in JG cells. At no time during
development was ALK-5, ALK-1 or ALK-2 immunoreactivity
detected in blood vessels or in renin expressing cells.
In interpreting the current findings, it is useful to first consider
the value of immunohistochemical detection of TGF-b receptors.
In cultured cells, type I and type II TGF-b receptors are ubiqui-
tously expressed, and physical association between TGF-b type I
and type II receptors is necessary for signal transduction [26].
Absence of functional TbR-II can lead to tumor formation in
colonic cells [27] and some breast carcinoma cells [28], and
absence of type I receptor abrogates TGF-b mediated signals [26].
Therefore, failure to observe TGF-b type I or II receptor immu-
noreactivity at some stages of development or in some cell types
is more likely a reflection of low levels of receptor expression than
a complete absence of receptors, though it is also possible that
ubiquitous TGF-b receptor expression is an artifact of culture.
Proof that TGF-b receptors are entirely absent from some cells
Fig. 4. Profile of staining intensity (0 to 41) for a-smooth muscle (a-SM) actin, transforming growth factor-beta type II receptor (TbR-II), and renin
in renal stroma, interlobular arteries, afferent arterioles and JG cells as a function of developmental stage. Kidneys from three to nine rats each were
evaluated at gestational days 15, 17 and 19 (E15, E17, E19), on postnatal days 1, 5, 10 and 30 (P1, P5, P15, P30) and at maturity (M).
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Fig. 3. Localization of a-smooth muscle (a-SM) actin, transforming growth factor-beta type II receptor (TbR-II), and renin immunoreactivity in
developing and mature kidneys. Sections from gestational day 17 (E17; A-C), postnatal day 10 (D-F) and adult (G, H) rat kidneys were stained with
a-SM actin (A, D), TbR-II (B, E, G), or renin (C, F, H) antibodies. Magnification: 3140 (A-C, E, F); 370 (D); 3207 (G, H). Stromal staining (3)
for a-SM actin, TbR-II and renin is observed within the kidneys at E17 (A-C). Afferent arteriolar immunoreactivity for a-SM actin, TbR-II and renin
is observed on postnatal day 10 (D-F). Panels G and H show co-localization of TbR-II (G) and renin (H) immunoreactivity in JG cells of mature rats.
Fig. 5. Localization of activin like kinases (ALK)-5, transforming growth factor-beta type II receptor (TbR-II) and ALK-1/2 immunoreactivity in
kidneys from postnatal day 1 and mature rats. Sections of kidneys from postnatal day 1 (A-C) and mature (D-F) rats were stained with ALK-5 (A, D),
TbR-II (B, E), or ALK-1/2 (C, F). Magnifications: 335 (A-C); 3140 (D-F). On postnatal day 1, ALK-5 was expressed predominantly in proximal tubules
() (A), some TbR-II and ALK-1/2 immunoreactivity were also seen in proximal tubule cells (). In the neonatal rat kidney, TbR-II staining was
localized predominantly in the stroma (3); ALK-1/2 immunoreactivity was observed in and ureteric bud structures (f) and in calyceal transitional
epithelium (7). The latter also stained positive for TbR-II on postnatal day 1. In mature kidney, ALK-5 (D) and ALK-1/2 (F) immunoreactivity was
not detected, and TbR-II expression was confined to JG cells (E).
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would require demonstration that functional responses to TGF-bs
are absent. Nevertheless, the extremely intense expression of
TbR-II with a distinct temporal and spatial pattern in this study
strongly suggests a functional role for this receptor in renal VSMC
development and in JG cells, the nature of which remains to be
resolved.
The distribution of a-SM actin expressing cells during renal
development has previously been described in detail by Carey,
Carey and Gomez [22], who found a-SM actin positive cells in the
E15 rat only in the mesenchyma surrounding the kidney, not
within. We similarly found a-SM actin expression in developing
aorta and in perirenal stromal cells on gestational day 15. TbR-II
immunoreactivity, though weaker than that of a-SM actin, was
observed in the same locations in cells surrounding, but not within
E15 kidney. In keeping with the absence of TbR-II in E15
kidneys, Wang et al [29] reported TbR-II mRNA expression in
stromal cells surrounding the E15.5 kidney of mice, and Iseki et al
[30] found no TbR-II mRNA in mouse kidney at E15. By
gestational day 17, we found a-SM actin expression within the
kidney in two distinct locations: in loosely organized, lace-like
stromal cells (Fig. 3A), as described by Carey et al [22], and in
easily discernible invading artery alongside the developing ureter
(Fig. 1D). At E17, TbR-II and, to a lesser extent renin, were also
found in the loose stromal cells (Fig. 3 B, C). Renin was not
observed in the VSMC of invading renal artery, and TbR-II in this
location was weak or absent. As development progressed, stromal
TbR-II and a-SM actin immunoreactivity continued to be intense,
peaking on postnatal day 1, and disappearing by postnatal day 15
(Fig. 4B and Fig. 2 D, E). The appearance of a-SM actin, TbR-II
and renin immunoreactive cells first in perirenal stroma and two
days later, at E17, in renal stromal cells suggests that stromal
TbR-II positive cells migrate into the kidney from a perirenal
location, though not as part of the VSMC layer of the invading
blood vessel. Grafting of E15 or earlier kidneys into neonatal host
kidneys expressing a marker such as b-galactosidase, as was done
by Robert et al [3] in exploring endothelial cell precursors in the
kidney, would be necessary to prove the extrarenal origin of the
putative TbR-II positive stromal cells. The findings that VSMC of
invading renal artery do not appear to express renin or TbR-II,
whereas the stromal cells are positive, also suggest that there may
be two distinct VSMC lineages that form renal blood vessels. In
keeping with this hypothesis is the report by Topouzis and
Majesky [13], who found two distinct VSMC lineages in chick
embryos, an ectodermally-derived cell type found in large arteries,
and a VSMC type derived from local mesoderm. It is of note that
Topouzis and Majesky [13] observed that the ectodermally de-
rived VSMC responded to TGF-b with proliferation, while growth
of the mesodermally derived cells was inhibited, and that only
immature, unglycosylated TbR-II was expressed by ectodermally
derived VSMC while the functional, glycosylated TbR-II was
expressed in the mesodermally derived cells. Our own findings of
TbR-II positive/a-SM actin positive cells in renal stroma and
TbR-II negative/a-SM actin positive cells in invading renal artery
would be consistent with the view that the stromal cells represent
a mesodermally-derived VSMC lineage distinct from the VSMC
of the invading aorta. Alternatively, it is also possible that the
VSMC of invading artery are already more fully differentiated
and therefore express little or no TbR-II.
Beginning on gestational day 19, TbR-II and renin immunore-
activity were also associated with the VSMC layer of developing
blood vessels located just below the zone of nephrogenesis (Fig. 1
G-I). Thereafter, arterial and arteriolar VSMC immunoreactivity
for TbR-II and renin was intense, persisting in afferent arterioles
through postnatal days 15 and 10, for TbR-II and renin, respec-
tively. The progressive association of TbR-II immunoreactivity
with the VSMC layer of renal arteries and arterioles is consistent
with the idea that the stromal cells expressing TbR-II are VSMC
precursors, which may be recruited into the appropriate location
around endothelial cell tubes through as yet undefined signals.
Regression of TbR-II immunoreactivity from the developing
blood vessels so that expression in mature kidneys was confined
only to JG cells, followed a centrifugal pattern similar to that
previously described for renin [31], though disappearance of
TbR-II from afferent arterioles occurred slightly later than renin.
Coordinate expression of TbR-II and renin during renal vascular
development and in mature JG cells implies that similar mecha-
nisms regulate TbR-II and renin expression, or that one system
positively regulates expression of the other.
Evidence that TGF-b signaling systems interact with the renin-
angiotensin system has previously been reported. Horikoshi et al
[32] first described markedly increased TGF-b2, but not TGF-b1
or TGF-b3 (ligands for TbR-II; Fig. 6), accumulation and co-
localization with renin in JG cells and the VSMC layer of
interlobular arteries in severely water-deprived mice, though
TGF-b2 was expressed at very low levels in the renal vasculature
of normal rats and mice. Similarly, water deprivation, dietary
potassium depletion and administration of angiotensin converting
enzyme inhibitors in rats are associated with JG cell hypertrophy,
extension of renin expression to interlobular arteries and in-
creased expression of TGF-b2, but not TGF-b1 or TGF-b3, in
these locations [33]. Enhanced TGF-b2 expression has also been
observed in infants with juxtaglomerular apparatus (JGA) hyper-
trophy due to renal artery stenosis and ischemic acute renal
failure [34]. Though it was initially hypothesized that TGF-b2
production in the JG cells may be under the control of angiotensin
II [32], the finding of enhanced TGF-b2 synthesis in the presence
of an ACE inhibitor favors an angiotensin II-independent mech-
anisms for the regulation of TGF-b2 accumulation in JG cells
[33]. Whether renin or angiotensin I might directly regulate
TGF-b2 expression at these sites remains an interesting possibil-
ity.
Angiotensin II also influences the TGF-b system. Induction of
TGF-b1 expression by angiotensin II in VSMC [35], mesangial
cells [36] and renal epithelial cells [37] has been described, and
vascular remodeling observed in cases of excess local angiotensin
II may be mediated by TGF-b1 [38, 39]. However, such findings
would not necessarily predict high levels of TbR-II expression in
vascular compartments where angiotensin II is abundant, as
TbR-II expression is markedly down-regulated by TGF-b1 [40].
Direct effects of angiotensin II on TbR-II expression have not
been described so far. Nevertheless, pharmacologic inhibition of
angiotensin converting enzyme in the immediate postnatal period
in the rat leads to marked abnormalities in development of the
vascular tree [41], and absence of angiotensin converting enzyme
expression in knockout mice is also associated with abnormal
vascular and JG cell development [42]. Thus, angiotensin II seems
to be necessary for normal renal vascular development. The
strong expression of TbR-II in developing renal VSMC and in
mature JG cells found in this study, taken together with previous
findings of angiotensin II-mediated TGF-b1 release and TGF-b1
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effects in vascular remodeling, suggest that an interaction between
angiotensin II and TGF-b signaling pathways operate in regulat-
ing the formation of the renal vasculature.
An interaction of the TGF-b system in JG cells and nitric oxide
(NO) produced by macula densa cells also needs to be considered.
In the kidney, neuronal NO synthase (nNOS) localizes exclusively
to macula densa cells of the ascending limb of Henle and may
operate to regulate renin secretion by JG cells [42–44]. TGF-b1 is
known to stimulate expression of endothelial cell NOS, and
strongly inhibits inducible NOS [45], though an effect of TGF-b
on neuronal NOS has not been described. Further, NO may
mediate some of the cellular actions of TGF-b, for instance in
vitro capillary morphogenesis [46]. The close physical relationship
between NO producing macula densa cells and TbR-II/TGF-b2
expressing JG cells raises the possibility that NO might also
regulate TGF-b action in JG cells.
An interesting finding in this study is the failure of ALK-1 and
ALK-2 or, as previously reported [21] ALK-5 (the predominant
TGF-b type I receptor), immunoreactivity to co-localize with
TbR-II in stromal, developing VSMC and JG cells. We previously
noted strong co-localization of TbR-II and ALK-5 in the ureteric
bud and proximal tubule epithelial cells of developing kidney [21].
Functional effects of TGF-b1 on tubule branching have previously
been noted [47, 48] and were addressed in a previous study from
this laboratory [21]. In the current study, developing calyceal
transitional epithelial cells were strongly labeled with both TbR-II
and ALK-1/2 (Fig. 5 B, C), suggesting an important role for
TGF-b, acting via ALK-1 or ALK-2, on the development of
transitional epithelium. The current understanding of TGF-b
signaling is that it requires an association between TbR-II and a
TGF-b receptor type I [49]. The receptors for activin and bone
morphogenic proteins belong to the same superfamilies as the
TGF-b type I and II receptors, and their signaling cascades
similarly depend on dimerization between type I and type II
receptors (Fig. 6). ALK-5 is the predominant type I receptor for
TbR-II. In addition, ALK-1 can interact with TbR-II and activin
type II receptor, while ALK-2 associates predominantly with
activin type II receptors, though it too can bind and be activated
by ligand-occupied TbR-II. If ALK-5, ALK-1, or ALK-2 serve as
signaling partner for TbR-II in developing VSMC and JG cells,
Fig. 6. Schematic representation of the
transforming growth factor-beta (TGF-b)
signaling cascade (A) and summary of ligand-
receptor associations in the TGF-b receptor
superfamily (B). (A) TGF-b ligands are
homodimers that require accessory receptors
(type III receptors) to bind type II receptor
serine threonine kinase (TbR-II). The binding
event results in recruitment of the type I
receptor serine threonine kinase (TbR-I) into
the complex. TbR-II kinase then
phosphorylates and activates TbR-I (also
known as activin like kinases, ALK). The Smad
signaling molecules exist as trimers within the
cell. Smad-2 trimers transiently associate with,
and are phosphorylated by activated TbR-I
kinase. Phosphorylated Smad-2 trimers then
associate with Smad-4 trimers with consequent
translocation into the nucleus and interaction
with specific transcription factors (TF) [54]. (B)
TGF-b, activin, and bone morphogenic proteins
(BMP) belong to the same superfamily of
ligands. Two distinct accessory type III
receptors are known, namely b-glycan which is
expressed by most cells, and endoglin,
expressed by many endothelial cells. Expression
of endoglin in the absence of b-glycan results in
TGF-b2 unresponsiveness. Distinct type II
receptors exist for the three families of ligands.
Alk-5 is the predominant TbR-I; ALK-1, ALK-
2 and ALK-4 interact predominantly with type
II activin receptors, but can also interact with
TbR-II.
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strong co-expression of these receptors would be expected, as was
observed in the epithelial cell locations. It is possible the TGF-b
type I isoform receptor expressed in the stromal VSMC precur-
sors, VSMC of developing renal vessels and mature JG cells has
eluded detection because a different TGF-b type I receptor, for
instance ALK-3, ALK-6, or ALK-4, even though they interact
most avidly with bone morphogenic protein type II (ALK-3 and
ALK-6) and activin type II (ALK-4) receptors. Another possibility
is that an ALK-5 splicing variant, which fails to interact with the
antibodies employed in this study, is expressed in the developing
VSMC and in JG cells. Splicing variants of ALK-5 have been
described [50, 51], but they do not involve the cytoplasmic region
of ALK-5 against which the antibody used in the current study is
directed. Another possibility, namely that the TbR-II antibody
used in this study cross-reacts with activin or bone morphogenic
protein type II receptors, and that type I receptors which interact
predominantly with TbR-II would therefore not be found, is also
not likely. Cross-reactivity of our antibody with activin and BMP
receptors type II was ruled out by the manufacturer, and is
furthermore unlikely given that there is , 33% sequence similar-
ity between them and TbR-II in the region against which the
antibody is directed. It is conceivable that the functional role of
TbR-II in the putative stromal VSM precursors, the developing
VSMC and in JG cells differs from that in cells where type I and
type II receptors are expressed in similar abundance. This possi-
bility is attractive because a similar dissociation between TbR-II
and type I receptors has previously been observed in cardiac
ventriculocytes in the postnatal period [52]. In that study, type I
receptor mRNA was expressed at much lower levels than TbR-II.
If TbR-II were expressed in vast excess of any type I receptor, it
might bind ligand competitively without fruitful type I receptor
interaction and thus act to inhibit TGF-b signaling. Indeed, excess
expression and homodimer formation of TbR-II in cultured cells
can inhibit TGF-b function through a dominant negative effect
[53]. Hence, excess TbR-II by forming unproductive homodimers
upon binding TGF-b could sequester the TGF-b ligand at the cell
surface. The possibility that signals, perhaps triggered by TGF-b2
in renin producing cells, are transduced through TbR-II indepen-
dently of any type I receptor also must be considered.
In summary, this study shows that putative stromal precursors
of renal VSMC express TbR-II, and that TbR-II immunoreactive
cells become associated with developing blood vessels in the
kidney as a function of developmental stage. Coordinate expres-
sion and regression of TbR-II and renin in renal VSMC, and
continued co-expression of TbR-II and renin in mature JG cells
further suggest a functional relationship between TGF-b and
angiotensin II in renal development and in differentiated JG cells.
The failure to observe typical TGF-b type I receptors in these
vascular locations further suggests that an as yet unknown type I
TGF-b receptor or receptor isoform mediates signaling in these
cells, or that TbR-II serves a distinct function at these sites.
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APPENDIX
Abbreviations used in this article are: ALK, activin like kinases; a-SM
actin, a-smooth muscle actin; E number, gestational day; JG, juxtaglomer-
ular; JGA, juxtaglomerular apparatus; M, mature; NGS, normal goat
serum; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; NOS,
nitric oxide synthase; P number, postnatal day; PDGF, platelet-derived
growth factor; TbR-II, TGF-b type II receptors; TBS, Tris buffered saline;
TGF-b, transforming growth factor-beta; VSMC, vascular smooth muscle
cells.
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